Equities research analysts expect Inovio Pharmaceuticals, Inc. (NASDAQ:INO) to report $14.04 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Inovio Pharmaceuticals’ earnings. The lowest sales estimate is $7.20 million and the highest is $20.87 million. Inovio Pharmaceuticals posted sales of $12.54 million during the same quarter last year, which would indicate a positive year over year growth rate of 12%. The business is expected to announce its next earnings results on Wednesday, November 8th.

According to Zacks, analysts expect that Inovio Pharmaceuticals will report full year sales of $14.04 million for the current year, with estimates ranging from $41.80 million to $72.61 million. For the next fiscal year, analysts expect that the firm will post sales of $32.52 million per share, with estimates ranging from $28.80 million to $36.23 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Inovio Pharmaceuticals.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $20.41 million for the quarter, compared to the consensus estimate of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. Inovio Pharmaceuticals’s revenue for the quarter was up 229.2% on a year-over-year basis. During the same period last year, the company posted ($0.26) EPS.

Several analysts have issued reports on INO shares. Stifel Nicolaus reissued a “buy” rating and set a $11.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, April 25th. BNP Paribas reissued a “neutral” rating and set a $39.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, May 1st. Jefferies Group LLC reissued a “neutral” rating and set a $38.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, May 1st. Nomura reissued a “buy” rating and set a $40.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, May 1st. Finally, Maxim Group reissued a “buy” rating on shares of Inovio Pharmaceuticals in a report on Thursday, May 11th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $20.78.

TRADEMARK VIOLATION WARNING: “Inovio Pharmaceuticals, Inc. (INO) Expected to Post Quarterly Sales of $14.04 Million” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/19/inovio-pharmaceuticals-inc-ino-expected-to-post-quarterly-sales-of-14-04-million.html.

In other news, Director David B. Weiner sold 8,000 shares of the company’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the completion of the transaction, the director now owns 740,956 shares of the company’s stock, valued at $5,927,648. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.60% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Wasatch Advisors Inc. raised its position in Inovio Pharmaceuticals by 43.6% in the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after buying an additional 793,306 shares during the period. Vanguard Group Inc. raised its position in Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after buying an additional 226,861 shares during the period. Candriam Luxembourg S.C.A. acquired a new position in Inovio Pharmaceuticals during the second quarter worth $1,411,000. GSA Capital Partners LLP acquired a new position in Inovio Pharmaceuticals during the second quarter worth $1,035,000. Finally, Virtu KCG Holdings LLC acquired a new position in Inovio Pharmaceuticals during the second quarter worth $556,000. 22.96% of the stock is owned by hedge funds and other institutional investors.

Shares of Inovio Pharmaceuticals (NASDAQ:INO) traded up 1.68% during mid-day trading on Friday, hitting $5.45. 838,819 shares of the company were exchanged. The firm has a 50 day moving average of $6.43 and a 200 day moving average of $6.78. Inovio Pharmaceuticals has a 12-month low of $5.28 and a 12-month high of $9.86. The company’s market capitalization is $491.74 million.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.